Gregory J Wilson, Benigno Rodriguez, Shuying Sue Li, Mary Allen, Ian Frank, Erika Rudnicki, Meg Trahey, Spyros Kalams, Drew Hannaman, David K Clarke, Rong Xu, Michael Egan, John Eldridge, Michael Pensiero, Theresa Latham, Guido Ferrari, David C Montefiori, Georgia D Tomaras, Stephen C De Rosa, Jeffrey M Jacobson, Maurine D Miner, Marnie Elizaga
BACKGROUND: HIV subtypes B and C together account for around 60% of HIV-1 cases worldwide. We evaluated the safety and immunogenicity of a subtype B DNA vaccine prime followed by a subtype C viral vector boost. METHODS: Fourteen healthy adults received DNA plasmid encoding HIV-1 subtype B nef/tat/vif and env (n = 11) or placebo (n = 3) intramuscularly (IM) via electroporation (EP) at 0, 1, and 3 months, followed by IM injection of recombinant vesicular stomatitis virus encoding subtype C Env or placebo at 6 and 9 months...
March 17, 2023: Vaccine